Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at

Equities research analysts at started coverage on shares of Organovo (NASDAQ:ONVOGet Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Stock Performance

NASDAQ ONVO opened at $0.91 on Thursday. The firm’s 50 day moving average price is $1.01 and its two-hundred day moving average price is $1.05. Organovo has a twelve month low of $0.85 and a twelve month high of $2.05. The stock has a market cap of $13.02 million, a price-to-earnings ratio of -0.42 and a beta of 0.68.

Organovo Company Profile

(Get Free Report)

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.

Further Reading

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with's FREE daily email newsletter.